A Sign of IPOs to Come?
Clovis Prices Within Range; Adds $130M for Cancer Trials
By Jennifer Boggs
Thursday, November 17, 2011
Clovis Oncology Inc., a small, development-stage firm based in Boulder, Colo., has done what no other biotech has managed this year: priced its initial public offering (IPO) actually within its initial range.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.